Retrieved from https://studentshare.org/finance-accounting/1680722-aceto-10k
https://studentshare.org/finance-accounting/1680722-aceto-10k.
The company has warehouses worldwide with a strong presence in some countries such as the United States, United Kingdom, China, and Germany. The companies are primarily located in the United States, Europe, and Asia-Pacific regions. The customers range from small enterprises to large firms (Aceto, 2014).
The financial analysis was from the fiscal year that ended on June 30, 2014. The Human Health segment had net sales of $160,217, which represented a 23.6% increase from the previous year. The Pharmaceutical Ingredients segment had a net sale of $176,425, a 4.6% decrease from the prior year. The Performance Chemicals segment had net sales of $173,537, a decrease of 6.3% from the previous year. The Pharmaceutical Ingredients section seems to be the largest contributor to the net income of the company followed by the Performance Chemicals segment. Ironically, the two significant contributors dropped yet the overall net sales of the company increased by 2.1% to $510,179. It seems the vast rise in the Health Segment was enough to buffer the shortcomings in the other segments (Aceto, 2014).
The company faces a lot of risks that could affect its financial performance in the future. Being a business that first sources before distributing products, it faces a significant challenge in case some of its suppliers close down or decide to sell their products. Also, low-quality products from the suppliers can affect the company’s image if the goods manage to reach the consumers. Another risk factor that could face the company is the increasing invention of new technology in the health and pharmaceutical fields. For example, genetic engineering and gene-based medications could pose a big threat to the products of the company.
Read More